<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03656055</url>
  </required_header>
  <id_info>
    <org_study_id>2016_32</org_study_id>
    <secondary_id>2017-A00194-49</secondary_id>
    <nct_id>NCT03656055</nct_id>
  </id_info>
  <brief_title>Analysis of Neurodegenerative Process Within Visual Ways In Multiple Sclerosis</brief_title>
  <acronym>VWIMS</acronym>
  <official_title>Study of the Link Between Retinal Atrophy and Demyelinating Inflammatory Processes on Visual Pathways in Relapsing Multiple Sclerosis in Magnetic Resonance Imaging and Optical Coherence Tomography</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will interest in the pathophysiology of silent retinal axonal loss in multiple
      sclerosis. Recent studies have suggested that silent retinal axonal loss (no past history of
      optic neuritis [ON]) may be due to inflammatory lesions within the optic radiations and a
      transsynaptic degenerative process. The objective is to measure the exact role of silent
      optic nerve lesion in the occurrence of silent retinal axonal loss by performing OCT, brain
      and optic nerve MRI in a cohort of patients without recent disease activity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will interest in the neurodegenerative process reported in multiple sclerosis
      within the visual ways.

      Symptomatic and asymptomatic retinal axonal loss in multiple sclerosis (MS) have largely been
      described. Many recent optical coherence tomography (OCT) studies have suggested that
      subclinical retinal axonal loss (no past history of optic neuritis [ON]) observed in MS
      mainly due to inflammatory and demyelinating lesions within the optic radiations and a
      retrograde transsynaptic degenerative process. None of these studies clearly tried to
      investigate the role of asymptomatic optic nerve lesion(s) in subclinical retinal axonal loss
      occurence.

      The main objective of the study is to measure the exact role of silent optic nerve lesion in
      the occurrence of silent retinal axonal loss by performing OCT, brain and optic nerve MRI.
      The study will focus on a cohort of patients without recent disease activity in order to
      exclude or minimize the risk of recent and old lesion occurence on the visual ways, which
      could be a bias in our analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 21, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Study of asymptomatic retinal atrophy in multiple sclerosis and asymptomatic optic nerve demyelinating lesion</measure>
    <time_frame>Day 1 (cross-sectional study)</time_frame>
    <description>The temporal peripapillary Retinal Nerve Fiber Layer thickness (pRNFL; quantitative data) measured on optical coherence tomography will evaluate asymptomatic retinal atrophy
Presence of subclinical optic nerve lesion will be assessed on optic nerve MRI (3D-double inversion recovery sequence; Y/N; qualitative data) and according to clinical information (past history of optic neuritis [ON] or not). It will enable investigators to define 3 eyes' groups: eyes' group with symptomatic optic nerve lesion (ON eyes), eyes' group with asymptomatic optic nerve lesion (NON eyes with asymptomatic lesion) and eyes' group without symptomatic or asymptomatic lesion (NON eyes without lesion).
Investigators will proceed to comparison of temporal pRNFL between NON eyes with asymptomatic lesion and NON eyes without lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the link between asymptomatic retinal atrophy in multiple sclerosis and intensity of demyelinating process all along the optic ways (from the retina to the visual cortex)</measure>
    <time_frame>Day 1 (cross-sectional study)</time_frame>
    <description>Within NON eyes, investigators will evaluate the imaging parameters on the optic ways which is/are significantly and independently associated to temporal pRNFL (multivariate analysis)
MRI parameters parameters included will be: length of asymptomatic optic nerve lesion; presence of lesion on chiasma, presence of lesion on optic tracts, T2 lesion burden on optic radiations, fractional anisotropy in optic radiations, volume of primary visual cortex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the link between symptomatic retinal atrophy in multiple sclerosis and intensity of demyelinating process all along the optic ways (from the retina to the visual cortex)</measure>
    <time_frame>Day 1 (cross-sectional study)</time_frame>
    <description>Within ON eyes, investigators will evaluate the imaging parameters on the optic ways which is/are significantly and independently associated to temporal pRNFL (multivariate analysis)
MRI parameters parameters included will be: length of subclinical optic nerve lesion; presence of lesion on chiasma, presence of lesion on optic tracts, T2 lesion burden on optic radiations, fractional anisotropy in optic radiations, volume of primary visual cortex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the link between retinal atrophy and visual connectivity</measure>
    <time_frame>Day 1 (cross-sectional study)</time_frame>
    <description>Within all eyes (ON eyes + NON eyes with asymptomatic optic nerve lesion + NON eyes without asymptomatic lesion), investigators will evaluate the link between the mean temporal pRNFL of both eyes (pRNFL; quantitative data) and the strength of visual connectivity (seed based approach on resting state sequence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the link between visual disability and MRI parameters measuring intensity of demyelinating process all along the optic ways (from the retina to the visual cortex)</measure>
    <time_frame>Day 1 (cross-sectional study)</time_frame>
    <description>Within all eyes (ON eyes + NON eyes with asymptomatic optic nerve lesion + NON eyes without asymptomatic lesion), investigators will evaluate the MRI parameters significantly and independently associated to visual disability.
Visual disability will be measured by low contrast vision acuity (2.5%; unit LogMar)
MRI parameters will be length of subclinical optic nerve lesion; presence of lesion on chiasma, presence of lesion on optic tracts, T2 lesion burden on optic radiations, fractional anisotropy in optic radiations, volume of primary visual cortex</description>
  </secondary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Multiple Sclerosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        RRMS treated by natalizumab for more than 6 months in order to measure patients with a
        lower risk of relapse
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsing Remitting Multiple Sclerosis (RRMS) patients treated by natalizumab for more
             than 6 months

          -  JohnCunninghamVirus (JCV) index &lt; 0.9

          -  patients followed in our MS center from the beginning of the disease

        Exclusion Criteria:

          -  ophthalmologic diseases

          -  diabetes mellitus

          -  contra-indication to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier Outteryck, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olivier Outteryck, MD, PhD</last_name>
    <phone>03 20 44 68 46</phone>
    <phone_ext>+33</phone_ext>
    <email>olivier.outteryck@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Roger Salengro, CHRU</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier Outteryck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Hodel J, Outteryck O, Bocher AL, Zéphir H, Lambert O, Benadjaoud MA, Chechin D, Pruvo JP, Vermersch P, Leclerc X. Comparison of 3D double inversion recovery and 2D STIR FLAIR MR sequences for the imaging of optic neuritis: pilot study. Eur Radiol. 2014 Dec;24(12):3069-75. doi: 10.1007/s00330-014-3342-3. Epub 2014 Aug 23.</citation>
    <PMID>25149294</PMID>
  </reference>
  <reference>
    <citation>Hadhoum N, Hodel J, Defoort-Dhellemmes S, Duhamel A, Drumez E, Zéphir H, Pruvo JP, Leclerc X, Vermersch P, Outteryck O. Length of optic nerve double inversion recovery hypersignal is associated with retinal axonal loss. Mult Scler. 2016 Apr;22(5):649-58. doi: 10.1177/1352458515598021. Epub 2015 Jul 30.</citation>
    <PMID>26227005</PMID>
  </reference>
  <reference>
    <citation>Gabilondo I, Martínez-Lapiscina EH, Martínez-Heras E, Fraga-Pumar E, Llufriu S, Ortiz S, Bullich S, Sepulveda M, Falcon C, Berenguer J, Saiz A, Sanchez-Dalmau B, Villoslada P. Trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. Ann Neurol. 2014 Jan;75(1):98-107. doi: 10.1002/ana.24030. Epub 2014 Jan 2.</citation>
    <PMID>24114885</PMID>
  </reference>
  <reference>
    <citation>Jindahra P, Petrie A, Plant GT. The time course of retrograde trans-synaptic degeneration following occipital lobe damage in humans. Brain. 2012 Feb;135(Pt 2):534-41. doi: 10.1093/brain/awr324. Epub 2012 Feb 1.</citation>
    <PMID>22300877</PMID>
  </reference>
  <reference>
    <citation>Petzold A, Balcer LJ, Calabresi PA, Costello F, Frohman TC, Frohman EM, Martinez-Lapiscina EH, Green AJ, Kardon R, Outteryck O, Paul F, Schippling S, Vermersch P, Villoslada P, Balk LJ; ERN-EYE IMSVISUAL. Retinal layer segmentation in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol. 2017 Oct;16(10):797-812. doi: 10.1016/S1474-4422(17)30278-8. Epub 2017 Sep 12. Review.</citation>
    <PMID>28920886</PMID>
  </reference>
  <reference>
    <citation>Martinez-Lapiscina EH, Arnow S, Wilson JA, Saidha S, Preiningerova JL, Oberwahrenbrock T, Brandt AU, Pablo LE, Guerrieri S, Gonzalez I, Outteryck O, Mueller AK, Albrecht P, Chan W, Lukas S, Balk LJ, Fraser C, Frederiksen JL, Resto J, Frohman T, Cordano C, Zubizarreta I, Andorra M, Sanchez-Dalmau B, Saiz A, Bermel R, Klistorner A, Petzold A, Schippling S, Costello F, Aktas O, Vermersch P, Oreja-Guevara C, Comi G, Leocani L, Garcia-Martin E, Paul F, Havrdova E, Frohman E, Balcer LJ, Green AJ, Calabresi PA, Villoslada P; IMSVISUAL consortium. Retinal thickness measured with optical coherence tomography and risk of disability worsening in multiple sclerosis: a cohort study. Lancet Neurol. 2016 May;15(6):574-84. doi: 10.1016/S1474-4422(16)00068-5. Epub 2016 Mar 18.</citation>
    <PMID>27011339</PMID>
  </reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>August 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2018</study_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRI</keyword>
  <keyword>axonal loss</keyword>
  <keyword>MS</keyword>
  <keyword>OCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

